Bacha Dhouha, Amor Anissa Ben, Farhat Farah Ben, Slama Sana Ben, Lahmar Ahlem, Bouraoui Saadia, Triki Amel
Service d'Anatomie Pathologique, Hôpital Mongi Slim, La Marsa, Tunisie.
Service de Gynécologie Obstétrique, Hôpital Mongi Slim, La Marsa, Tunisie.
Pan Afr Med J. 2020 Sep 17;37:70. doi: 10.11604/pamj.2020.37.70.20223. eCollection 2020.
markers in breast cancer stem cells, such as cluster of differentiation 10 (CD10), would be correlated with invasive and metastatic potential of several types of cancer, contributing to tumor growth and metastases. In patients with breast cancer, its prognostic value is still controversial, given the discrepancy of results. The purpose of the study was to study CD10 expression in stromal cells of patients with breast cancer as well as to evaluate the prognostic value of this expression.
we conducted a retrospective, descriptive and prognostic study. It involved 57 patients with invasive cancer of no special type, whose data were collected in the Department of Pathological Anatomy at the Mongi Slim Hospital over a 38-month period. CD10 expression was studied immunohistochemically and interpreted by semi-quantitative scoring system based on three categories with thresholds of 10 and 30%.
the average age of patients was 56.4 years. Twenty-eight patients (49%) had labeled CD10 stromal, half of patients had a score of 1 (low) and the other half had 2 (high). This labeling significantly reduced recurrence-free survival (p=0.001). However, it had no influence on overall survival (p=0.84). The correlation study showed that CD10 expression in stromal cells was significantly correlated with 12 poor prognostic factors in patients with breast cancer.
CD10 expression in stromal cells of invasive breast cancer is a poor prognostic factor, predictive of poor survival without recurrence and associated with a high invasive and metastatic potential.
乳腺癌干细胞中的标志物，如分化簇10（CD10），与多种癌症的侵袭和转移潜能相关，促进肿瘤生长和转移。在乳腺癌患者中，鉴于结果的差异，其预后价值仍存在争议。本研究的目的是研究乳腺癌患者基质细胞中CD10的表达，并评估这种表达的预后价值。
我们进行了一项回顾性、描述性和预后性研究。研究对象为57例非特殊类型浸润性癌患者，其数据在蒙吉·斯利姆医院病理解剖科38个月期间收集。通过免疫组织化学研究CD10表达，并采用基于10%和30%阈值的三类半定量评分系统进行解读。
患者的平均年龄为56.4岁。28例（49%）患者的基质细胞CD10呈阳性，一半患者评分为1（低），另一半评分为2（高）。这种标记显著降低了无复发生存率（p=0.001）。然而，它对总生存率没有影响（p=0.84）。相关性研究表明，基质细胞中CD10的表达与乳腺癌患者的12个不良预后因素显著相关。
浸润性乳腺癌基质细胞中CD10的表达是一个不良预后因素，预示着无复发生存不良，且与高侵袭和转移潜能相关。
